JP2024526237A5 - - Google Patents
Info
- Publication number
- JP2024526237A5 JP2024526237A5 JP2023580418A JP2023580418A JP2024526237A5 JP 2024526237 A5 JP2024526237 A5 JP 2024526237A5 JP 2023580418 A JP2023580418 A JP 2023580418A JP 2023580418 A JP2023580418 A JP 2023580418A JP 2024526237 A5 JP2024526237 A5 JP 2024526237A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- derived
- cell
- population
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218204P | 2021-07-02 | 2021-07-02 | |
| US63/218,204 | 2021-07-02 | ||
| US202163265190P | 2021-12-09 | 2021-12-09 | |
| US63/265,190 | 2021-12-09 | ||
| US202263341943P | 2022-05-13 | 2022-05-13 | |
| US63/341,943 | 2022-05-13 | ||
| PCT/US2022/073396 WO2023279112A1 (en) | 2021-07-02 | 2022-07-01 | Protected effector cells and use thereof for allogeneic adoptive cell therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526237A JP2024526237A (ja) | 2024-07-17 |
| JP2024526237A5 true JP2024526237A5 (https=) | 2025-07-09 |
Family
ID=84690870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580418A Pending JP2024526237A (ja) | 2021-07-02 | 2022-07-01 | 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240307540A1 (https=) |
| EP (1) | EP4363557A4 (https=) |
| JP (1) | JP2024526237A (https=) |
| KR (1) | KR20240031361A (https=) |
| AU (1) | AU2022304599A1 (https=) |
| CA (1) | CA3223323A1 (https=) |
| IL (1) | IL309797A (https=) |
| MX (1) | MX2023015376A (https=) |
| WO (1) | WO2023279112A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326274A (en) * | 2023-08-02 | 2026-04-01 | Fate Therapeutics Inc | A targeted scaffold for solid tumors that promotes effector cell differentiation and function |
| WO2025055927A1 (en) * | 2023-09-13 | 2025-03-20 | Qihan Hong Kong Limited | Immunotherapies using hypoimmunogenic engineered cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| JP2020528885A (ja) * | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| IL316257A (en) * | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| CN114258429A (zh) * | 2019-07-17 | 2022-03-29 | 菲特治疗公司 | 免疫效应细胞工程化和其用途 |
| US20230016034A1 (en) * | 2019-12-06 | 2023-01-19 | Fate Therapeutics, Inc. | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS |
-
2022
- 2022-07-01 AU AU2022304599A patent/AU2022304599A1/en active Pending
- 2022-07-01 EP EP22834452.9A patent/EP4363557A4/en active Pending
- 2022-07-01 WO PCT/US2022/073396 patent/WO2023279112A1/en not_active Ceased
- 2022-07-01 US US18/575,734 patent/US20240307540A1/en active Pending
- 2022-07-01 CA CA3223323A patent/CA3223323A1/en active Pending
- 2022-07-01 JP JP2023580418A patent/JP2024526237A/ja active Pending
- 2022-07-01 MX MX2023015376A patent/MX2023015376A/es unknown
- 2022-07-01 IL IL309797A patent/IL309797A/en unknown
- 2022-07-01 KR KR1020247004057A patent/KR20240031361A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541441A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| Xu et al. | Natural killer cell-based immunotherapy for acute myeloid leukemia | |
| JP2021505131A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| JP2022510207A5 (https=) | ||
| JP2023505206A5 (https=) | ||
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| JP2023530704A5 (https=) | ||
| JP2023548467A5 (https=) | ||
| CA3107675A1 (en) | Improving the efficacy and safety of adoptive cellular therapies | |
| JP2023549098A5 (https=) | ||
| EP3291835B1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same | |
| JP2023548829A5 (https=) | ||
| JP2024502157A (ja) | 樹状細胞活性化キメラ抗原受容体及びその使用 | |
| DK3029137T3 (en) | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF | |
| JP2023545992A5 (https=) | ||
| US12203098B2 (en) | Cells having solid tumor targeting backbone and use thereof | |
| KR20210033941A (ko) | 개선된 t-세포 요법 | |
| KR20250133399A (ko) | 유전자 전달 및 합성 및 면역 수용체의 활성을 제어하기 위한 방법 및 조성물 | |
| JP2024526237A5 (https=) | ||
| JP2024515920A5 (https=) | ||
| JP2025506515A (ja) | 血中のキメラ抗原受容体細胞のブースト | |
| JP2024540237A5 (https=) | ||
| CN118339178A (zh) | 包括白细胞介素-9受体信号传导结构域的嵌合抗原受体 |